Articles by R. Christian Moreton - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by R. Christian Moreton

R. Christian Moreton

vice-president, pharmaceutical sciences

R. Christian Moreton, PhD, is vice-president of pharmaceutical sciences at Finnbrit Consulting and a member of Pharmaceutical Technologys editorial advisory board.

Articles
Toward Expanding Understanding
March 2, 2011

A revised book on process analytical technology could be valuable to novices and experts.

Flexible Approaches to Accommodate Excipient Variability Using the Principles of QbD
May 1, 2010

The authors review new regulatory expectations and describe potential approaches to accommodate excipient variability. This article is part of PharmTech's supplement "Solid Dosage and Excipients 2010."

The Continuing Story of Nanoparticles
November 2, 2007

A book illustrates the potential for nanoparticulate drug delivery, and how much about them remains to be understood.

Manufacturing One Trend at a Time
October 2, 2007

Change is inevitable, as is contract manufacturing. But which companies will survive the drifts?

Functionality and Performance of Excipients
October 1, 2006

This article provides an overview of functionality, functionality-related characteristics, and excipients performance.

Excipient Functionality
May 2, 2004

The author suggests that an excipient's functionality can only be determined in the context of a specific formulation and manufacturing process.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
FindPharma Custom Search
Click here